Related Experiment Video
Updated: Aug 27, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition
Bingfeng Luo1, Yuan Yuan1, Yifei Zhu1
1Division of Urology, Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Objective:
To investigate the effects of miRNA-145-5p on the tumor development and progression of prostate cancer (Pca) bone metastasis.
Methods:
Levels of miRNA-145-5p were assessed by real-time quantitative PCR in PC3 (bone metastatic Pca cells), 22RV1 (non-metastatic Pca cells), RWPE-1 (non-cancerous prostate epithelial cells) and Pca tissues collected from patients with and without bone metastases. The impact of miRNA-145-5p on cell proliferation was tested by CCK8 assay, colony formation assay and flow cytometric cell cycle analysis. Effects on invasion and migration of PC3 cells were determined by Transwell and wound healing assays. Western blotting, enzyme-linked immunosorbent assay, and flow cytometry apoptosis analyses were also performed to assess roles in metastasis.
Results:
Levels of miRNA-145-5p were decreased in Pca bone metastases and miRNA-145-5p inhibited cell proliferation, migration and invasion. miRNA-145-5p inhibited the expression of basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF) and transforming growth factor-β (TGF-β) in PC3 cells. miR-145-5p increased the expression of the epithelial marker E-cadherin and reduced the expression of matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). It was found that miRNA-145-5p mediated the epithelial-mesenchymal transition (EMT) and induced apoptosis.
Conclusions:
miRNA-145-5p negatively regulated the EMT, inhibited Pca bone metastasis and promoted apoptosis in Pca bone metastasis. Mimicry of miRNA-145-5p action raises the possibility of a novel target for treating Pca with bone metastases.
Insights
MicroRNA-145-5p inhibits prostate cancer bone metastasis by reducing cell proliferation, migration, and epithelial-mesenchymal transition. This microRNA promotes apoptosis, offering a potential therapeutic target for prostate cancer bone metastases.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis Research
Background:
- Prostate cancer (Pca) bone metastasis is a significant challenge in advanced disease.
- Understanding the molecular mechanisms regulating Pca bone metastasis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of microRNA-145-5p (miRNA-145-5p) in the development and progression of prostate cancer bone metastasis.
Main Methods:
- Real-time quantitative PCR was used to assess miRNA-145-5p levels in Pca cells and tissues.
- Cell proliferation, migration, invasion, and apoptosis were evaluated using various assays (CCK8, colony formation, Transwell, wound healing, flow cytometry).
- Protein and growth factor expression (bFGF, IGF, TGF-β, E-cadherin, MMP-2, MMP-9) were analyzed via Western blotting and ELISA.
Main Results:
- miRNA-145-5p levels were decreased in Pca bone metastases.
- Overexpression of miRNA-145-5p inhibited Pca cell proliferation, migration, and invasion.
- miRNA-145-5p suppressed key factors involved in epithelial-mesenchymal transition (EMT) and promoted apoptosis.
Conclusions:
- miRNA-145-5p acts as a tumor suppressor by inhibiting EMT and promoting apoptosis in prostate cancer bone metastasis.
- miRNA-145-5p represents a potential therapeutic target for treating prostate cancer with bone metastases.
More Related Videos
Related Concept Videos
01:22MicroRNAs
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...